Keros Therapeutics (KROS) Competitors $14.16 +0.12 (+0.85%) Closing price 05/22/2025 04:00 PM EasternExtended Trading$14.00 -0.16 (-1.13%) As of 04:48 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KROS vs. AMRX, AAPG, MIRM, OGN, APLS, ARWR, GMTX, VCEL, BLTE, and NAMSShould you be buying Keros Therapeutics stock or one of its competitors? The main competitors of Keros Therapeutics include Amneal Pharmaceuticals (AMRX), Ascentage Pharma Group International (AAPG), Mirum Pharmaceuticals (MIRM), Organon & Co. (OGN), Apellis Pharmaceuticals (APLS), Arrowhead Pharmaceuticals (ARWR), Gemini Therapeutics (GMTX), Vericel (VCEL), Belite Bio (BLTE), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical products" industry. Keros Therapeutics vs. Amneal Pharmaceuticals Ascentage Pharma Group International Mirum Pharmaceuticals Organon & Co. Apellis Pharmaceuticals Arrowhead Pharmaceuticals Gemini Therapeutics Vericel Belite Bio NewAmsterdam Pharma Amneal Pharmaceuticals (NASDAQ:AMRX) and Keros Therapeutics (NASDAQ:KROS) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk, media sentiment and community ranking. Which has higher earnings and valuation, AMRX or KROS? Amneal Pharmaceuticals has higher revenue and earnings than Keros Therapeutics. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmneal Pharmaceuticals$2.83B0.80-$83.99M-$0.04-179.75Keros Therapeutics$214.71M2.68-$152.99M-$0.18-78.67 Does the MarketBeat Community prefer AMRX or KROS? Keros Therapeutics received 47 more outperform votes than Amneal Pharmaceuticals when rated by MarketBeat users. However, 95.24% of users gave Amneal Pharmaceuticals an outperform vote while only 70.53% of users gave Keros Therapeutics an outperform vote. CompanyUnderperformOutperformAmneal PharmaceuticalsOutperform Votes2095.24% Underperform Votes14.76%Keros TherapeuticsOutperform Votes6770.53% Underperform Votes2829.47% Do analysts prefer AMRX or KROS? Amneal Pharmaceuticals currently has a consensus price target of $11.50, indicating a potential upside of 59.94%. Keros Therapeutics has a consensus price target of $37.00, indicating a potential upside of 161.30%. Given Keros Therapeutics' higher possible upside, analysts clearly believe Keros Therapeutics is more favorable than Amneal Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amneal Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Keros Therapeutics 0 Sell rating(s) 6 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.57 Which has more risk & volatility, AMRX or KROS? Amneal Pharmaceuticals has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Comparatively, Keros Therapeutics has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500. Do institutionals & insiders hold more shares of AMRX or KROS? 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are held by institutional investors. 26.6% of Amneal Pharmaceuticals shares are held by insiders. Comparatively, 20.6% of Keros Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is AMRX or KROS more profitable? Amneal Pharmaceuticals has a net margin of -6.88% compared to Keros Therapeutics' net margin of -27,890.94%. Keros Therapeutics' return on equity of -41.74% beat Amneal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Amneal Pharmaceuticals-6.88% -346.26% 4.85% Keros Therapeutics -27,890.94%-41.74%-38.42% Does the media refer more to AMRX or KROS? In the previous week, Keros Therapeutics had 2 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 9 mentions for Keros Therapeutics and 7 mentions for Amneal Pharmaceuticals. Keros Therapeutics' average media sentiment score of 1.34 beat Amneal Pharmaceuticals' score of 1.01 indicating that Keros Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Keros Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryKeros Therapeutics beats Amneal Pharmaceuticals on 10 of the 18 factors compared between the two stocks. Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KROS vs. The Competition Export to ExcelMetricKeros TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$575.11M$6.48B$5.33B$8.39BDividend YieldN/A2.64%5.21%4.11%P/E Ratio-2.729.0626.7119.71Price / Sales2.68251.50386.13120.55Price / CashN/A65.8538.2534.62Price / Book1.286.456.774.50Net Income-$152.99M$143.98M$3.23B$248.22M7 Day Performance0.93%2.41%1.80%0.56%1 Month Performance1.94%4.56%11.10%13.17%1 Year Performance-72.30%-2.67%17.11%7.30% Keros Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KROSKeros Therapeutics3.2455 of 5 stars$14.16+0.9%$37.00+161.3%-72.3%$575.11M$214.71M-2.72100Positive NewsAMRXAmneal Pharmaceuticals3.2546 of 5 stars$7.19-1.2%$11.50+60.1%+8.1%$2.26B$2.83B-10.587,600Positive NewsAAPGAscentage Pharma Group InternationalN/A$25.50+1.5%N/AN/A$2.22B$980.65M0.00600News CoveragePositive NewsGap DownMIRMMirum Pharmaceuticals4.0709 of 5 stars$44.01-0.7%$60.73+38.0%+68.0%$2.19B$379.25M-21.85140Positive NewsAnalyst RevisionOGNOrganon & Co.4.7951 of 5 stars$8.40-0.4%$18.00+114.4%-60.4%$2.18B$6.29B2.5210,000APLSApellis Pharmaceuticals4.2027 of 5 stars$17.30-0.7%$40.42+133.7%-59.2%$2.18B$775.84M-8.53770Analyst ForecastARWRArrowhead Pharmaceuticals3.5164 of 5 stars$15.34+0.2%$42.13+174.7%-38.8%$2.12B$545.21M-2.97400News CoverageAnalyst ForecastAnalyst RevisionGMTXGemini TherapeuticsN/A$48.89-2.4%N/A+56.4%$2.12BN/A-48.8930News CoverageVCELVericel2.6721 of 5 stars$41.09+0.0%$61.14+48.8%-17.8%$2.07B$238.54M686.61300Positive NewsAnalyst ForecastBLTEBelite Bio2.0346 of 5 stars$63.84-5.1%$96.67+51.4%+43.5%$2.03BN/A-57.5110Analyst DowngradeNAMSNewAmsterdam Pharma2.6699 of 5 stars$18.41-0.5%$43.00+133.6%-6.6%$2.03B$47.14M-9.844Positive NewsAnalyst Downgrade Related Companies and Tools Related Companies Amneal Pharmaceuticals Alternatives Ascentage Pharma Group International Alternatives Mirum Pharmaceuticals Alternatives Organon & Co. Alternatives Apellis Pharmaceuticals Alternatives Arrowhead Pharmaceuticals Alternatives Gemini Therapeutics Alternatives Vericel Alternatives Belite Bio Alternatives NewAmsterdam Pharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KROS) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KROS Stock Free KROS Stock Alerts